Austria Works On Method To Improve Price Transparency

Understanding Public R&D Funding May Lead To Better Pricing Policies

Austria’s health technology appraisal institute aims to further discussion on public investments in R&D and medicines pricing transparency.

Best_Price
Austrian HTA Aims To Further Discussion On Price Transparency • Source: Shutterstock

Austria’s health technology appraisal body, the Ludwig Boltzman Institut, has developed a new methodology for shedding light on how much public funding has been invested in the R&D for high-cost drugs. Better understanding of public contributions could lead to improved pricing policies, says the institute.

The new “investigational search strategy,” outlined in a project report, is one piece of a bigger puzzle on how...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

European Industry Calls For Support As It Juggles Multiple Challenges

 
• By 

At Medicines for Europe’s legal and annual conferences in Brussels last week, multiple key issues competed for attention, giving the generics and biosimilars industry plenty to think about at a critical time for EU pharma reform.

England’s NHS Plan Eyes Cancer Vaccine Boost, Single Formulary & ‘Pay For Impact’ Drug Deal

 

The creation of a single national formulary for medicines prescribing that could impact industry is among the action points in the UK government’s new 10-year health plan for the National Health Service in England.

Denmark Sets New EU Benchmark With 14-Day Clinical Trial Review Timeline

 
• By 

Denmark is shaking up clinical trial timelines with a new process for reviewing applications for early-phase mono-national trials that is twice as fast as the standard timelines in the EU and the UK.

Industry Groups Back EU Life Sciences Strategy As Commission Pledges Clinical Trial Investment

 

Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.

More from Geography